Innoviva

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

In laboratory studies, zoliflodacin has been shown to be active against Neisseria gonorrhoeae including multidrug-resistant strains If approved, zoliflodacin could become the first new antibiotic treatment for gonorrhea in decades. 10 June 2025 -- Massachusetts, US and Geneva, Switzerland -- Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc, in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that...

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Oral presentation highlights new findings about the efficacy of XACDURO for the treatment of monomicrobial and polymicrobial Acinetobacter baumannii-calcoaceticus infections Researchers share global surveillance data on the in vitro activity of XERAVA (eravacycline) for injection on resistant isolates and Gram-positive clinical pathogens Total of nine presentations on XACDURO and XERAVA to be revealed during IDWeek 2023 11 October 2023 -- Massachusetts, UK -- Innoviva...
Boston BioHub 35 Gatehouse Drive Waltham, MA USA 02451